INS and metabolic dysfunction-associated steatotic liver disease: In biopsy-proven NAFLD patients, SREBF-2 predicted the presence of NASH and extensively affected tissue insulin sensitivity, pancreatic β-cell function, and lipoprotein and adipokine responses to fat ingestion.